Clinical Trial Search

Primary: Percentage Change in the Ratio of Mean-normalized Perfusion Within Ventilation Defective Regions Relative to Outside — -17.8 percentage

Primary: Asthma Control Test — 19.3; 19.8; 19.1; 19.6 units on a scale — p=0.8

Primary: Difference in ASM Mass Between Groups

Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2

Primary: Concentration (pg/ml) of CXCL8 Cytokine in Cell Supernatant After Stimulation (IFN/TNF or IL13) and Treatment (VR588, FP or CP) Conditions in ALI Cultured Epithelial…

Primary: Change From Baseline in Asthma Control at 18 Months — 1.27; 1.17 score on a scale

Primary: Change in TSLP Gene Expression — 0.000197; 0.000035 Fold Change

Primary: Airway Symptom Scores Experienced by Subjects During the 1st 4 Days of the Infection — 8.72; 2.77 units on a scale — p=0.049

Primary: Maximum Symptom Days/14 Days — 2.7 days

Primary: FEV1 Percent Change Post-ipratropium — 10.8 percent change — p=0.032

Primary: Characterize Contribution of Histamine in Children With Asthma — 11253.24; 6464.20; 3539.67 flux units on a continuous scale

Primary: Gene Expression in Airway Secretions and Tissues — -0.66; 0.54; -0.30 Relative gene expression level

Primary: Percentage of Neutrophils in Peripheral Blood — 57.3; 55.4 percentage of neutrophils — p=0.53

Primary: Late Asthmatic Response (LAR) - Smokers: Absolute Change From Saline in Minimum Forced Expiratory Volume in One Second (FEV1) Between 4-10 Hours (Hrs) After Allergen…

Primary: Change in Number of Days Per Week, in the Previous 4 Weeks, of Daytime Asthma Symptoms From Baseline to 7-month Follow-up — -3.4; -2.8 days per week

Primary: Part A, Cohort-1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 3; 3; 3; 6 Participants

Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml

Primary: Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With…

Primary: Maximum Post-exercise Percent (%) Fall in FEV1 — 10.57; 13.82 Percent change from baseline — p=0.009

Primary: Central and Peripheral Elastance — 391; 461; 587; 334 cmH2O/L

Primary: Change From Baseline in the Percentage of Total White Blood Cell That Were Eosinophils at 48 Hours — 82.11 percent of white blood cells

Primary: Effect of Natural-source d-α-tocopheryl Acetate on the Baseline and Allergen-induced Levels of F2-isoprostanes in the Bronchoalveolar Lavage Fluid (BAL)

Primary: Total Number of Inflammatory Cells Recovered in Sputum — 2.3; 2.1; 1.9; 5.2 10^6 cells/ml — p=0.1

Primary: Rate of Asthma Exacerbations Per Year — 0.69; 0.82 Adjusted annualized exacerbations — p=0.048

Primary: Change in Airway Reactivity From Baseline (Visit 1) and 4 Weeks (Visit 2) — 3.0; 3.2; 5.3; 4.3 mg/mL

Primary: Number of Participants to Whom an AAP (Asthma Action Plan) Was Delivered by the Clinician — 0; 79 Participants

Primary: The Percentage of Participants With Asthma Who Rated the Use of the ELLIPTA Inhaler as Easy or Very Easy, Among Those Who Demonstrated Correct Use of the Inhaler at the…

Primary: Symptom-free Days in the Last 14 Days — 11.4; 11.6 days in prior 14d — p=0.93

Primary: GPA — 2.75; 2.61; 3.25; 2.50 GPA(unweighted)

Primary: Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period — 0.99; 1.06; 1.05 Asthma attacks within episodes per year — p=0.510